Jacobio Pharma doses first patient with Aurora A inhibitor JAB-2485 in phase 1/2a trial

Jacobio Pharma said that it has completed the first patient dosage of Aurora A inhibitor JAB-2485, its in-house R&D drug candidate, in a phase 1/2a ... Read More